Company news
Agios Pharmaceuticals, Inc. news in 2022
Agios Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
December 20, 2022
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
December 10, 2022
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual...
December 9, 2022
Agios Appoints Tsveta Milanova as Chief Commercial Officer
December 5, 2022
Agios to Participate in December Investor Conference
November 29, 2022
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
November 9, 2022
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
November 2, 2022
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
November 2, 2022
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
October 26, 2022
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
October 19, 2022
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
September 25, 2022
Agios Appoints Cecilia Jones as Chief Financial Officer
September 18, 2022
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
September 15, 2022
Agios to Participate in September Investor Conferences
August 23, 2022
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
August 17, 2022
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
August 14, 2022
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
August 10, 2022
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
August 7, 2022
Agios Reports Business Highlights and Second Quarter 2022 Financial Results
August 3, 2022
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
July 13, 2022
Agios Appoints Brian Goff as Chief Executive Officer
July 11, 2022
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
June 12, 2022
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
June 9, 2022
Agios Announces Evolution of Research Organization
May 15, 2022
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
May 11, 2022
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
May 9, 2022
Agios Reports Business Highlights and First Quarter 2022 Financial Results
May 4, 2022
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
April 20, 2022
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
April 13, 2022
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
February 16, 2022
Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
February 9, 2022
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
January 9, 2022
Calls in 2022
- Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2022 Earnings Call
Nov 3, 2022
Transcript - Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2022 Earnings Call
May 5, 2022
Transcript - Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2021 Earnings Call
Feb 24, 2022
Transcript